Peptides DB
Research-centric peptide and protocol reference hub
Study 31 of 33Survodutide (BI 456906) literatureLancet (London, England) · RCT · Phase 3Top journal2024

Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.

Survodutide did not show increased cardiovascular risk compared to placebo in adults with obesity at increased cardiovascular risk, but gastrointestinal side effects were more common.

Read at Lancet (London, England)Add to compare

Where it sits

this study against the rest of the survodutide (bi 456906) corpus
4
Preclinical
10
Observational
3
Open-label
11
Randomised · this one
5
Reviews

Summary and findings

This study assessed the cardiovascular safety of survodutide in adults with obesity at increased cardiovascular risk. Participants were randomly assigned to receive either 3.6 mg or 6.0 mg of survodutide or placebo. The primary endpoint was a composite of cardiovascular events, with results indicating non-inferiority of survodutide compared to placebo.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Hazard ratio for primary endpoint was 0.89 (95% CI 0.67-1.18; p<0.0001 for non-inferiority).n=5530Phase 32024

Abstract

The authors’ words, as Lancet (London, England) supplied them

<h4>Background</h4>Survodutide, a glucagon receptor and GLP-1 receptor dual agonist, improved markers of cardiometabolic health in people with obesity, but cardiovascular safety for this new class remains to be established.<h4>Methods</h4>SYNCHRONIZE-CVOT was a global, phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre, event-driven, cardiovascular safety trial conducted at 524 clinical sites in 34 countries. We included participants aged 18 years or older with a BMI of 27 kg/m<sup>2</sup> or greater and established cardiovascular disease or at least two obesity complications or risk factors for cardiovascular disease; participants with chronic kidney disease were eligible if they also had a BMI of 30 kg/m<sup>2</sup> or greater. Participants were randomly assigned by interactive response technology (1:1:1) to once-weekly subcutaneous survodutide (up-titrated to 3·6 mg or 6·0 mg) or placebo. The primary endpoint was a composite of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure event (targeting 189 primary endpoint events). We assessed the non-inferiority of pooled survodutide compared with placebo with a margin of 1·65 for the upper limit of the two-sided 95% CI of the hazard ratio (HR). Efficacy and safety analyses included all randomly assigned participants who received at least one dose of survodutide or placebo. The primary analysis was performed according to the treatment-regimen estimand, which assessed treatment effects regardless of any early discontinuation of survodutide or placebo, temporary stop, the use of protocol-prohibited obesity medications, or a prolonged dose-escalation period. This completed trial is registered with ClinicalTrials.gov, NCT06077864.<h4>Findings</h4>From Nov 20, 2023, to Nov 8, 2024, we screened 7753 participants, of whom 5530 (71·3%) participants were recruited and randomly assigned to treatment. 23 (0·4%) participants were not treated; 1836 (33·3%) of 5507 participants received survodutide 3·6 mg, 1835 (33·3%) received 6·0 mg, and 1836 (33·3%) received placebo; 2194 (39·8%) were female, 3313 (60·2%) were male, and 4332 (78·7%) were White. Median time in study was 22·0 months (IQR 20·1-23·7). 1029 (56·0%) in the survodutide 3·6 mg group, 1039 (56·6%) in the survodutide 6·0 mg group, and 1083 (59·0%) in the placebo group remained on treatment until study closeout. The primary endpoint occurred in 136 (3·7%) of 3671 participants in the survodutide group and in 76 (4·1%) 1836 participants in the placebo group (HR 0·89 [95% CI 0·67-1·18; p<0·0001 for non-inferiority). Adverse events occurred in 1708 (93·0%) of 1836 participants with survodutide 3·6 mg, 1708 (93·1%) of 1835 with survodutide 6·0 mg, and 1571 (85·6%) of 1836 with placebo. Gastrointestinal adverse events were more frequent with survodutide than in the placebo group (nausea occurred in 882 [48·0%] of 1836 participants in the 3·6 mg group and 900 [49·0%] of 1835 in the 6·0 mg group vs 223 [12·1%] of 1836 in the placebo group, and vomiting occurred in 582 [31·7%] participants in the 3·6 mg group and 623 [34·0%] in the 6·0 mg group vs 89 [4·8%] in the placebo group). Gastrointestinal adverse events leading to treatment discontinuations occurred in 354 (19·3%) participants in the survodutide 3·6 mg group, 381 (20·8%) in the survodutide 6·0 mg, and 34 (1·9%) in the placebo group. Serious adverse events occurred at similar rates across treatment groups (413 [22·5%] in the survodutide 3·6 mg group, 381 [20·8%] in the survodutide 6·0 mg, and 439 [23·9%] in the placebo group). Fatal adverse events were similar across treatment groups (16 [0·9%] in the survodutide 3·6 mg group, 16 [0·9%] in the survodutide 6·0 mg, and 11 [0·6%] in the placebo group) and were primarily due to cardiac disorders (six [0·3%] in the survodutide 3·6 mg group, seven [0·4%] in the survodutide 6·0 mg, and six [0·3%] in the placebo group).<h4>Interpretation</h4>In participants with obesity with established cardiovascular disease or chronic kidney disease or at increased risk of cardiovascular disease, survodutide was not associated with increased risk for the primary composite endpoint of death from cardiovascular causes, non-fatal stroke, non-fatal myocardial infarction, ischaemia-related coronary revascularisation, or heart failure event compared with placebo. This cardiovascular safety trial provides clinicians with reassuring data that treatment with survodutide, a novel glucagon receptor-GLP-1 receptor dual agonist, is not associated with increased cardiovascular risk.<h4>Funding</h4>Boehringer Ingelheim.

Background

This paper addresses the cardiovascular safety of survodutide, a dual agonist of glucagon and GLP-1 receptors, in individuals with obesity and increased cardiovascular risk. Previous studies indicated improvements in cardiometabolic markers, but the cardiovascular safety profile was not established. This trial is significant as it aims to provide data on cardiovascular outcomes in a high-risk population.

Methods

SYNCHRONIZE-CVOT was a phase 3, double-blind, randomized, placebo-controlled trial conducted at 524 sites across 34 countries. The study included participants aged 18 years or older with a BMI of 27 kg/m² or greater and established cardiovascular disease or obesity-related complications. Participants were assigned to receive either 3.6 mg or 6.0 mg of survodutide or placebo, with the primary endpoint being a composite of major cardiovascular events.

Results

The primary endpoint occurred in 136 (3.7%) of 3671 participants in the survodutide group compared to 76 (4.1%) of 1836 participants in the placebo group. The hazard ratio for the primary endpoint was 0.89 with a 95% confidence interval of 0.67-1.18, and the p-value for non-inferiority was less than 0.0001. Adverse events were reported in 93.0% of participants receiving survodutide 3.6 mg, with gastrointestinal events being notably higher than in the placebo group.

Interpretation

The findings suggest that survodutide does not increase cardiovascular risk compared to placebo, which aligns with prior literature on GLP-1 receptor agonists. However, the effect size is not clinically significant, and the high rate of adverse events, particularly gastrointestinal, raises concerns about tolerability. The study's limitations, including potential bias from industry funding and the relatively short follow-up, suggest caution in interpreting these results for long-term clinical practice.

Key findings

  • Primary endpoint occurred in 136 (3.7%) of 3671 participants in the survodutide group and in 76 (4.1%) of 1836 participants in the placebo group.
  • Hazard ratio (HR) for primary endpoint was 0.89 [95% CI 0.67-1.18; p<0.0001 for non-inferiority].
  • Adverse events occurred in 1708 (93.0%) of 1836 participants with survodutide 3.6 mg.
  • Nausea occurred in 882 (48.0%) of 1836 participants in the 3.6 mg group vs 223 (12.1%) in the placebo group.
  • Gastrointestinal adverse events leading to treatment discontinuations occurred in 354 (19.3%) participants in the survodutide 3.6 mg group.

Limitations

  • Industry-funded by Boehringer Ingelheim.
  • Follow-up duration of 22 months may not capture long-term safety.
  • High rate of gastrointestinal adverse events.
  • Not all participants completed the study treatment.
  • Single-site and multicenter nature may introduce variability.

Elsewhere in the Survodutide (BI 456906) corpus

DVisceral and Ectopic Fat Remodeling with Incretin-Based Therapies in Type 2 Diabetes: Human Imaging Evidence.Journal of multidisciplinary healthcare · 2026reviewAGLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.Digestive diseases (Basel, Switzerland) · 2023 · n=673 · RR 2.98 for MASH resolution without worsening of fibrosis; 95% CI 2.09-4.24; k=2.reviewASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2023 · n=752 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2.HumanASurvodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.Contemporary clinical trials · 2026 · 18.7% body-weight reduction at 46 weeks.reviewCNephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.Diabetes, obesity & metabolism · 2026 · Not reported in abstract.AnimalASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2Human